These studies indicate that selective ERK1/2 inhibitors, such as VTX11e [65], represent a rational drug combination choice with SRC inhibitor in both MEK inhibitor naïve and acquired trametinib‐resistant tumour cells. The gene discussed is MAPK3; the disease is neoplasm.